ToPanc Trial: Survival After Total Versus Partial Pancreaticoduodenectomy for Adenocarcinoma of the Pancreatic Head, Distal Cholangiocarcinoma, and Ampullary Cancer
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Total pancreatectomy (TP), Partial pancreaticoduodenectomy (PD).
- Who it may be relevant to
- Registry conditions: Pancreatic Cancer. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Germany, Switzerland
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
ToPanc Trial: Survival After Total Versus Partial Pancreaticoduodenectomy for Adenocarcinoma of the Pancreatic Head, Distal Cholangiocarcinoma, and Ampullary Cancer: a Multi-centric Randomized Controlled Trial
Overview
The goal of this clinical trial is to learn if total removal of the pancreas is a preferable alternative to partial removal in patients with cancer of the pancreatic head who are at high risk of pancreatic leakage. The main question it aims to answer is: Does total pancreas removal improve survival without reducing quality of life compared to partial removal? The only study specific procedures are the collection of 2 blood samples (7.5ml for each time point, preoperatively and during the hospitalisation) and the completion of the questionnaires.
Detailed description
The pancreas is located in the upper abdomen and has 2 main functions: Production of digestive juices and of insulin, the latter being most important for blood sugar regulation and energy conservation. Certain types of cancer in the pancreatic head are very aggressive, but with complete surgical removal of the tumor and additional chemotherapy cure is possible. For tumor resection, the head of the pancreas as well as duodenum and part of the bile duct are removed. 3 new connections are built: the remaining pancreas, bile duct and stomach are connected to a loop of small intestine.
This operation takes around 6 hours and leads to complications in 20-30% of cases. A serious complication and unfortunately the most frequent is the leaking of the pancreas remnant, with outflow of the aggressive digestive juice into the surrounding tissue. Consequences may be severe bleeding and/or infections. Many studies show that affected patients have an increased risk of tumor recurrence and a reduced survival.
To avoid pancreatic leak, the entire pancreas can be removed. So far, removal of the whole pancreas has only been chosen in cases of very advanced cancer. After both, partial or total pancreas removal, patients need to substitute digestive enzymes. This can be done by capsules, which need to be taken with every meal. But while some patients after partial removal maintain sufficient function to produce insulin, all patients after total removal are diabetic and need insulin injections. In the past, blood sugar control in the absence of insulin production was difficult and accompanied by low quality of life (QoL). This has changed tremendously by the introduction of continuous glucose monitoring (sensors, which are attached to the arm) and automated insulin delivery systems (also known as "artificial pancreas"). This development renders total pancreas removal a reasonable alternative, with the advantage, that only 2 new connections are made: One between the bile duct and small intestine and one between the stomach and the small intestine.
Study question: Is removal of the whole pancreas in patients at high risk of a pancreatic leakage a preferable alternative to partial removal?
For this study, patients with cancer of the pancreatic head who are planned for surgery can be included. These patients will be randomly assigned to two groups:
1. Standard group: partial removal of the pancreas 2. Study group: total removal of the pancreas
Both techniques are safe and are established techniques to treat cancer in the pancreatic head. After the operation, many clinical data will be recorded. The two most important factors will be survival and quality of life, which will be assessed by questionnaires on a regular base. Additionally, postoperative complications, chemotherapy rates, tumor recurrence and many more data will be monitored.
Interventions
- Procedure Total pancreatectomy (TP)
The investigators perform TP in patients who undergo surgical resection of a malignant tumor in the pancreatic head. - Procedure Partial pancreaticoduodenectomy (PD)
The investigators perform partial PD with anastomosis of the pancreas in patients who undergo surgical resection of a malignant tumor in the pancreatic head. This is the current standard procedure.
Primary outcome measures
- Overall survival (OS) [Time frame: At 2 years]
Secondary outcome measures (12)
- Quality of Life (QoL) Pancreatic Cancer [Time frame: At 0.5 year, at 1 year, at 2 years]
- Quality of Life (QoL) Diabetes [Time frame: At 0.5 year, at 1 year, at 2 years]
- Postoperative complications (discriminating minor and major complications) [Time frame: Within 90 day of surgery]
- Mortality [Time frame: Within 90 days of surgery]
- Length of hospital stay in days [Time frame: Within 90 days of surgery]
- Re-admission [Time frame: Within 90 days of surgery]
- Re-operation [Time frame: Within 90 days of surgery]
- Adjuvant Chemotherapy (ACT) initiation [Time frame: At 1 year]
- Adjuvant Chemotherapy (ACT) completion [Time frame: At 1 year]
- Disease-Free Survival (DFS) [Time frame: At follow-up, up to 4.5 years]
- Functional status [Time frame: At 0.5 year, at 1 year, at 2 years]
- Body Mass Index (BMI) [Time frame: At 0.5 year, at 1 year, at 2 years]
Eligibility criteria
Inclusion criteria
- Adult patients (age ≥ 18 years) scheduled to undergo PD for highly suspected or histologically proven, resectable pancreatic ductal adenocarcinoma (PDAC), distal cholangiocarcinoma (DCC), and/or ampullary cancer (pancreaticobiliary type)
- Suspected pancreas anastomosis at high-risk for development of a postoperative pancreatic fistula (POPF) (grade "D" according to Schuh et al. (29): Estimation by CT scan, MRI, and/or Endoscopic Ultrasound
- Written informed consent
Exclusion criteria
- Duodenal carcinoma, ampullary cancer (intestinal type), neuroendocrine tumors, benign tumors, chronic pancreatitis
- Medical conditions that do not allow appreciation of the nature, scope, and possible consequences of the trial as judged by the investigator
- Pregnancy. A beta-Human Chorionic Gonadotropin (bHCG) pregnancy test must to be performed for women of child-bearing potential (defined as premenopausal women who have not undergone surgical sterilization)
- Inability to follow the study procedures, e.g., due to psychological disorders, dementia, etc.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Open label
- Primary purpose
- Treatment
Study locations
Switzerland · 8 centers
- Department of General and Visceral Surgery, Kantonsspital Aarau — Aarau
- Department of Surgery, Kantonsspital Baden — Baden
- Department of Visceral Surgery, University Hospital Basel — Basel
- Inselspital, Bern University Hospital — Bern
- Department of Visceral Surgery, University Hospital Geneva — Geneva
- Department of General, Visceral, Endocrine and Transplantation Surgery, Kantonsspital St. — Sankt Gallen
- Department of Surgery, Stadtspital Triemli Zürich — Zurich
- Department of Surgery and Transplantation, University Hospital Zürich — Zurich
Germany · 2 centers
- Department of General, Visceral and Transplantation Surgery, University Hospital Münster — Münster
- Department of General and Visceral Surgery, University Hospital Ulm — Ulm
Identifiers
NCT: NCT06801899 · 2024-02010